Publication Name	World Journal of Gastroenterology
Manuscript ID	5318
Country	United States

Received	2013-08-29 09:12
Peer-Review Started	2013-08-29 16:28
To Make the First Decision	2013-12-16 17:48
Return for Revision	2013-10-16 11:14
Revised	2013-10-31 20:08
Second Decision	2014-01-20 16:44
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-01-20 18:02
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-02-27 21:30
Publish the Manuscript Online	2014-03-06 14:13

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Opioid growth factor and the treatment of human pancreatic cancer: A review
Manuscript Source	Invited Manuscript
All Author List	Ian S Zagon and Patricia J McLaughlin
Funding Agency and Grant Number	Funding Agency Grant Number NIH (in part) Philip Morris United States Pennsylvania Department of Heath Paul I and Anna E Shockey Family Foundation
Corresponding Author	Patricia J McLaughlin, Professor, Department of Neural and Behavioral Sciences, Pennsylvania State University College of Medicine, MC-H109, 500 University Drive, Hershey, PA 17033, United States. pxm9@psu.edu
Key Words	Enkephalins; DNA synthesis; Pancreatic adenocarcinoma; Opioids; Nude mice; Receptor transfection
Core Tip	Opioid growth factor (OGF) biotherapy for human pancreatic cancer is based on inhibition of DNA synthesis by upregulation of cyclin-dependent inhibitory kinases. Preclinical studies using human pancreatic cancer cell lines have demonstrated that OGF interaction with its selective receptor OGF receptor (OGFr) is a physiological determinant of cell proliferation. Addition of OGF to standard chemotherapies enhances the efficacy of treatment. Studies in nude mice confirm that the OGF-OGFr axis regulates pancreatic cancer progression. Clinical trials using OGF for treatment of patients with unresectable pancreatic tumors reveal that OGF is a novel endogenous opioid that is safe, non-toxic, elicits negligible side effects and reduces pancreatic tumor size in persons who have failed other therapies.
Publish Date	2014-03-06 14:13
Citation	Zagon IS, McLaughlin PJ. Opioid growth factor and the treatment of human pancreatic cancer: A review. World J Gastroenterol 2014; 20(9): 2218-2223
URL	http://www.wjgnet.com/1007-9327/full/v20/i9/2218.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i9.2218

Full Article (PDF)	WJG-20-2218.pdf
Full Article (Word)	WJG-20-2218.doc
Manuscript File	5318-Review.doc
Answering Reviewers	5318-Answering reviewers.pdf
Copyright License Agreement	5318-Copyright agreement.pdf
Peer-review Report	5318-Peer review(s).pdf
Scientific Editor Work List	5318-Scientific editor work list.doc